(19)
(11) EP 3 489 353 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.08.2023 Bulletin 2023/35

(45) Mention of the grant of the patent:
26.07.2023 Bulletin 2023/30

(21) Application number: 19151187.2

(22) Date of filing: 21.11.2016
(51) International Patent Classification (IPC): 
C12N 5/10(2006.01)
C12N 7/04(2006.01)
 C12N 7/02(2006.01)
C12N 15/85(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 5/10; C12N 7/025; C12N 7/045; C12N 15/85; C12N 2740/16052

(54)

STABLE CELL LINES FOR RETROVIRAL PRODUCTION

STABILE ZELLLINIEN FÜR DIE RETROVIRALE PRODUKTION

LIGNÉES CELLULAIRES STABLES POUR LA PRODUCTION DE RÉTROVIRUS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 24.11.2015 GB 201520761
26.05.2016 GB 201609303

(43) Date of publication of application:
29.05.2019 Bulletin 2019/22

(62) Application number of the earlier application in accordance with Art. 76 EPC:
16798512.6 / 3380604

(73) Proprietor: GlaxoSmithKline Intellectual Property Development Limited
Stevenage SG1 2NY (GB)

(72) Inventors:
  • JOHNSON, Sabine
    Stevenage, Hertfordshire SG1 2NY (GB)
  • PALLANT, Celeste
    Stevenage, Hertfordshire SG1 2NY (GB)
  • VAMVA, Eirini
    Stevenage, Hertfordshire SG1 2NY (GB)
  • VINK, Conrad
    Stevenage, Hertfordshire SG1 2NY (GB)

(74) Representative: Wilkinson, Johanna Elise 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-00/66758
WO-A1-95/03400
WO-A1-2017/089307
WO-A2-03/064665
GB-A- 2 538 321
US-A1- 2012 142 049
 WO-A1-01/91802
WO-A1-2012/028681
WO-A2-02/072836
WO-A2-2012/170431
GB-A- 2 538 324
   
  • M. NIEBERT ET AL: "Characterization of Chromosomally Assigned Replication-Competent Gamma Porcine Endogenous Retroviruses Derived from a Large White Pig and Expression in Human Cells", JOURNAL OF VIROLOGY., vol. 76, no. 6, 15 March 2002 (2002-03-15) , pages 2714-2720, XP055332042, US ISSN: 0022-538X, DOI: 10.1128/JVI.76.6.2714-2720.2002
  • YAJIN NI ET AL: "Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 7, no. 6, June 2005 (2005-06), pages 818-834, XP002664828, ISSN: 1099-498X, DOI: 10.1002/JGM.726 [retrieved on 2005-02-03]
  • Félix Recillas-Targa: "Mammalian Gene Transfer and Expression : Multiple Strategies for Gene Transfer, Expression, Knockdown, and Chromatin Influence in Mammalian Cell Lines and Transgenic Animals", MOLECULAR BIOTECHNOLOGY, vol. 34, no. 3 November 2006 (2006-11), November 2006 (2006-11), pages 337-357, XP055338237, Retrieved from the Internet: URL:http://rd.springer.com/content/pdf/10. 1385/MB:34:3:337.pdf [retrieved on 2017-01-23]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).